Regeneron uses its 30 years of research experience to invent a wide range of investigational drugs with a mission to help move the human condition forward. Besides robust research and an impressive pipeline in eye disease, cancer, asthma, atopic dermatitis, and pain, Regeneron is trying to tackle COVID-19 with the investigational antibody therapy REGN-COV2, currently being studied for treatment and prevention of the fatal virus.
- In August 2019, the PALM trial of 681 Ebola patients in the Democratic Republic of the Congo was stopped early when preliminary results showed that REGN-EB3 crossed the pre-specified superiority threshold for preventing death compared to the control arm, ZMapp. The trial investigators thought it would be unethical to continue to give Ebola patients any therapeutics other than the two top-performing ones, led by REGN-EB3.
- Regeneron is currently researching REGN-COV2, an investigational antibody cocktail, as a treatment and preventative therapy for COVID-19. The company’s work looks promising, having produced hundreds of virus-neutralizing antibodies in genetically engineered mice and identified similarly performing antibodies from human COVID-19 survivors. This June, the company moved the two potent antibodies that form REGN-COV2 into cell production lines for large-scale manufacturing purposes and began clinical trials, and preliminary results announced in September showed it reduced viral loads and improved symptoms in non-hospitalized COVID-19 patients.
- The company’s responsibility strategy centers on three key areas: improve the lives of people with serious diseases; foster a culture of integrity and excellence; and build sustainable communities.
- In June 2020, Regeneron was named to The Civic 50, the largest initiative dedicated to volunteer service in the U.S., for the fourth consecutive year and honored for the first time as the sector leader for healthcare.
- In July 2020, Regeneron announced the winners of the 2020 Regeneron Science Talent Search with Society for Science & the Public.
- In 2020, Regeneron launched ambitious environmental targets focused on four areas: greenhouse gas emissions, energy, water, and waste. These include a goal of zero waste at all Regeneron sites by 2021, improve water efficiencies by 2025 with a global mapping and water stewardship program, and match 100% of electricity consumption with electricity from certified renewable sources by 2035.
- The Regeneron Way launched in 2019, containing the company’s refreshed cultural values and behaviors. They underscore the key attributes that drive Regeneron’s success and guide its hiring and employee engagement programs.
- Regeneron is committed to supporting colleagues and local communities during the pandemic. For instance, through Regeneron’s COVID-19 Double Matching Gift Campaign, the company helped its employees donate $750,000 to charities.
- Regeneron invests a great deal in encouraging young minds to pursue STEM and get excited about all research areas. For years they’ve put together day-long learning experiences known as Kids’ Day, which involves 500+ students, requires at least 150 employee volunteers, and costs about $30,000 for food and supplies.